Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Dividend History BEAM

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Dividend Analytics BEAM

Max Ratio

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Forward Annual Dividend Yield
Consecutive Years
Forward Annual Dividend – USD
Consistent Years
Dividend CAGR 3Y
Continuous Dividends
Dividend CAGR 5Y
Payout Ratio TTM
Dividend CAGR 10Y
Ex Dividend Date

Beam Therapeutics Inc

BEAM
Current price
21.16 USD -0.87 USD (-3.95%)
Last closed 22.03 USD
ISIN US07373V1052
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 2 274 113 024 USD
Yield for 12 month -17.41 %
1Y
3Y
5Y
10Y
15Y
BEAM
21.11.2021 - 28.11.2021

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease; BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. It also intends to develop BEAM-103, an anti-CD117 monoclonal antibody, and BEAM-104, a cell therapy for development in sickle cell disease and beta-thalassemia; and BEAM-201 and other potential ex vivo CAR-T therapies. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts. Address: 238 Main Street, Cambridge, MA, United States, 02142

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

44.07 USD

P/E Ratio

Dividend Yield

Financials BEAM

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Key Figures BEAM

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Current Year

+63 518 000 USD

Last Year

+377 709 000 USD

Current Quarter

+7 470 000 USD

Last Quarter

+30 067 000 USD

Current Year

+41 593 000 USD

Last Year

-59 672 000 USD

Current Quarter

+7 470 000 USD

Last Quarter

+24 624 000 USD
EBITDA -408 700 000 USD
Operating Margin TTM -1 596.87 %
Price to Earnings
Return On Assets TTM -19.05 %
PEG Ratio
Return On Equity TTM -38.04 %
Wall Street Target Price 44.07 USD
Revenue TTM 63 578 000 USD
Book Value 11.52 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY 0.80 %
Dividend Yield
Gross Profit TTM -302 071 008 USD
Earnings per share -4.61 USD
Diluted Eps TTM -4.61 USD
Most Recent Quarter I 2025
Quarterly Earnings Growth YOY
Profit Margin

Stock Valuation BEAM

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 17.24
Price Sales TTM 35.77
Enterprise Value EBITDA -7.03
Price Book MRQ 1.92

Technical Indicators BEAM

For 52 Weeks

13.53 USD 35.25 USD
50 Day MA 17.83 USD
Shares Short Prior Month 21 731 372
200 Day MA 23.00 USD
Short Ratio 12.99
Shares Short 24 076 439
Short Percent 24.30 %